<DOC>
	<DOC>NCT01054300</DOC>
	<brief_summary>This is a Phase 1 pharmacokinetic, pharmacodynamic study to understand the manner in which the body responds to, as well as how the drug is handled by the body, with once vs twice daily dosing of ertugliflozin (PF-04971729, MK-8835) in participants with type 2 diabetes.</brief_summary>
	<brief_title>Effects Of Ertugliflozin (PF-04971729, MK-8835) In Participants With Type 2 Diabetes (MK-8835-040)</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<criteria>Patients with type 2 diabetes, on up to 2 acceptable oral antidiabetes drugs for at least 8weeks prior to study. Patients with type 1 diabetes, patients with stroke, unstable angina, heart attack in last 6months, uncontrolled blood pressure.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>